Update Major Perioperative IO in Resectable Gastric Cancer
Real world Unfit ECOG PS2 remain challenging
Chemo free Regimen looks very attractive here in Superselect pts
PDL1
MSI
Seem to have Massive influence in deciding its use
Efficacy Updates Collected with Toxicity
📊 GEJ Carcinoma (Gastroesophageal Junction) – Full Guideline-Based Management at a Glance!
Most GEJ adenocarcinomas are treated like esophageal or gastric cancer depending on Siewert type & stage.
This one-pager covers:
• Initial workup & essential biomarkers (HER2, PD-L1 CPS, MSI/dMMR, CLDN18.2, NGS)
• Perioperative FLOT now preferred (superior OS vs CROSS per ESOPEC)
• CROSS as alternative for bulky/borderline disease
• Adjuvant nivolumab (CheckMate-577) after CROSS if residual disease
• Biomarker-driven therapy in metastatic & unresectable settings
• High-yield clinical pearls
Perfect quick reference for fellows, residents & practicing oncologists! 🔖
Save | Share | Tag a colleague
Made with ❤️ by Dr Rupam Manna
Follow for more Cancer Concepts Explained → @DrRupamOncology
#GEJCancer #EsophagealCancer #GastricCancer #Oncology #MedTwitter #CancerGuidelines #FLOT #Immunotherapy
🚨 CLEOPATRA Trial – The Landmark That Changed HER2+ Metastatic Breast Cancer Forever!
Dual HER2 blockade (Pertuzumab + Trastuzumab + Docetaxel = THP) became first-line standard of care.
Key Results: • PFS: 18.5 vs 12.4 months
• OS: 56.5 vs 40.8 months (15.7-month absolute gain – one of the largest survival benefits ever seen in solid tumor oncology!)
No increase in cardiac toxicity. Practice-changing. Global standard.
Full visual summary in the image 👇
#Oncology #BreastCancer #HER2 #CLEOPATRA #CancerResearch
Cancer Concepts Explained by @DrRupamOncology
Follow for more landmark trial breakdowns! 🔥
@g_espinoza Banco Central de Bolivia (BCB) – Circular Externa N° 007/2024
@g_espinoza cuando se levantará esa circular? Soy Boliviana que vive en el exterior por estudios y aún no podemos retirar, cómprar, pagar con nuestras tarjetas de Bolivia. Si lee este mensaje, gracias un saludo